GAP possesses an innovative biopharmaceutical platform. As well as also having capability to boost this company in development of the immunotherapeutic cancer agents. Active immunization as a part of immunotherapy act by stimulating hosts antitumor responses through methods such as vaccination or cytokine administration. On the other hand, passive immunization act by preformed tumor-specific T cells or antibodies are transferred into the host. Antibodies like monoclonal antibody have been in clinical use for many years and have been redesigned and humanized for better safety and efficacy.

Examples of antibodies currently used for cancer therapy include Rituximab that act by targeting CD20 and is used to treat B cell lymphoma, and Trastuzamab, which act by inhibiting receptor signaling in HER-2-positive breast cancer. In adoptive transfer therapy, tumor-reactive T cells obtained from sources such as lymph nodes, peripheral blood, or tumors. Further which is then infused back into patients. The effectiveness of treatments with adoptively transferred T cells may also be enhanced by combining with patient lymphodepletion and/or the administration of factors that support the survival of the transferred cells such as IL-2, and in recent times IL-15 and IL-7.

Significant progress has also been made in enhancing antitumor responses through such methods as immunization using tumor-associated antigens or administration of cytokines or other adjuvants. Since it has become apparent that no single agent therapy will be sufficient to control recognized tumors, more effective cancer treatment strategies will require combination therapeutic approaches.

Both active and passive forms of cancer immunotherapy might probably be most effective when administered in combination with a reduction in tumor-induced immune suppression that permits effective and persistent responses against tumor. The number and idleness of the regulatory mechanisms against tumor that have been recognized attracted the major barriers that will need to be conquering to allow effective cancer immunotherapy.

However, given the vital role a host’s immune system plays in whether cancer progression occurs; and the potential of immunotherapeutic strategies for combating cancer, particularly metastatic disease, overcoming these barriers is an important pursuit for tumor immunologists. The elucidation of immunosuppressive networks and their components has also revealed potential targets, which if inhibited may be an effective strategy for the generation of more successful immunotherapy for cancer. We will discuss a number of tumor-associated mechanisms that result in immune suppression and review some of the methods scientists have developed to redress the balance towards efficacious antitumor responses.

A proficient, expert and skilled team of oncologists and researchers for immune based therapy and their related services are present in Global Allied Pharmaceuticals (GAP). We are working effectively and successfully to meet the unmet need for medications.

You can contact Global Allied Pharmaceuticals for immunotherapy related services and through visit on www.gapsos.com.

or

contact us at Global Allied Pharmaceuticals

160 Vista Oak Dr.

Longwood, FL 32779

Telephone: 321-445-1969